Algae Life Sciences Inc., supplier of AstaZine astaxanthin, says FDA had no objections to 239 structure-function claims the supplier recently submitted.
Algae Life Sciences Inc. (Irvine, CA), supplier of the AstaZine astaxanthin ingredient, says FDA had no objections to 239 structure-function claims the supplier recently submitted. The claims cover everything from eye health to brain, skin, and joint health and are now available to marketers using AstaZine in their products.
In total, the company submitted 241 variations of claims covering AstaZine’s main health applications: eye health, brain health, skin health/UV exposure, antiaging and DNA/cellular health, anti-inflammatory and joint/muscle/tendon health, sports/energy, heart health, immune health, and antioxidants. FDA did, however, object to two claims related to “inflammatory response,” the firm reports. The health claims the company says FDA did not object to include the following:
“We’ve been working for months to attain this landmark achievement, which now makes us the leader in this critical marketing category,” said Bob Capelli, executive vice president of global marketing, Algae Life Sciences, in a press release. “We have some extremely compelling claims that are now allowed for AstaZine. This will enable brands to successfully market astaxanthin with an incredible variety of health claims.”
AstaZine is produced from Haematococcus pluvialis microalgae in a 100% glass tube photobioreactor (PBR) closed system. Earlier this year, the company announced it gained Ecocert organic certification for its Haematococcus pluvialis production.
Algae Life Sciences is a subsidiary of BGG.
Nutritional Outlook magazine